MDM2 Antagonist Nutlin-3 Stimulates Global DNA Hydroxymethylation by Enhancing p53-TET1 Signaling Axis

被引:0
|
作者
Wu, Danni [1 ,2 ,3 ]
Li, Yao [1 ]
Li, Cuiping [1 ]
Zhong, Shangwei [1 ]
Liu, Baodong [1 ]
Hang, Haiying [4 ]
Wang, Hailin [1 ,2 ,3 ,5 ]
机构
[1] Chinese Acad Sci, Res Ctr Ecoenvironm Sci, State Key Lab Environm Chem & Ecotoxicol, Beijing 100085, Peoples R China
[2] Chinese Acad Sci, Inst Microbiol, China Gen Microbiol Culture Collect Ctr, State Key Lab Microbial Resources, Beijing 100101, Peoples R China
[3] Univ Chinese Acad Sci, Beijing 100049, Peoples R China
[4] Chinese Acad Sci, Inst Biophys, Key Lab Prot & Peptide Pharmaceut, Natl Lab Biomacromol, Beijing 100101, Peoples R China
[5] UCAS, Hangzhou Inst Adv Study, Sch Environm, Hangzhou 310000, Peoples R China
基金
中国国家自然科学基金;
关键词
5-HYDROXYMETHYLCYTOSINE; CANCER; TET1; P53; 5-METHYLCYTOSINE; DEMETHYLATION; GROWTH; EPIGENETICS; SUPPRESSION; ACTIVATION;
D O I
10.1021/acschembio.3c00247
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
DNA hydroxymethylation is involved in many biologicalprocesses,including nuclear reprogramming, embryonic development, and tumorsuppression. In this study, we report that an anticancer agent, nutlin-3,selectively stimulates global DNA hydroxymethylation in TP53 wild-type cancer cells as manifested by the elevation of 5-hydroxymethylcytosine(5hmC) in genomic DNA. In contrast, nutlin 3 fails to enhance DNAhydroxymethylation in TP53-mutated cancer cells.Consistently, nutlin-3 as a MDM2 antagonist only activates wild-typebut not mutated TP53. Furthermore, nutlin-3 doesnot alter the expression of TET1 but slightly reduces the expressionof TET2 and TET3 proteins. These TET family proteins are responsiblefor converting 5-methylcytosine (5mC) to 5hmC. Interestingly, TET1knockdown could significantly block the nutlin-3-induced DNA hydroxymethylationas well as TP53 and P21 activation.Immunoprecipitation analysis supports that p53 strongly interactswith TET1 proteins. These results suggest that nutlin-3 activates TP53 and promotes p53-TET1 interaction. As positivefeedback, the p53-TET1 interaction further enhances p53 activationand promotes apoptosis. Collectively, we demonstrate that nutlin-3stimulates DNA hydroxymethylation and apoptosis via a positive feedbackmechanism.
引用
收藏
页码:2240 / 2248
页数:9
相关论文
共 50 条
  • [11] Nutlin-3, an Antagonist of MDM2, Enhances the Radiosensitivity of Esophageal Squamous Cancer with Wild-Type p53
    He, Tianli
    Guo, Jiayou
    Song, Hongmei
    Zhu, Hongcheng
    Di, Xiaoke
    Min, Hua
    Wang, Yuandong
    Chen, Guangzong
    Dai, Wangshu
    Ma, Jianhua
    Sun, Xinchen
    Ma, Jianxin
    [J]. PATHOLOGY & ONCOLOGY RESEARCH, 2018, 24 (01) : 75 - 81
  • [12] Antitumor Activity of the Selective MDM2 Antagonist Nutlin-3 Against Chemoresistant Neuroblastoma With Wild-Type p53
    Van Maerken, Tom
    Ferdinande, Liesbeth
    Taildeman, Jasmien
    Lambertz, Irina
    Yigit, Nurten
    Vercruysse, Liesbeth
    Rihani, Ali
    Michaelis, Martin
    Cinatl, Jindrich, Jr.
    Cuvelier, Claude A.
    Marine, Jean-Christophe
    De Paepe, Anne
    Bracke, Marc
    Speleman, Frank
    Vandesompele, Jo
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (22): : 1562 - 1574
  • [13] The MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2
    Gu, Lubing
    Zhu, Ningxi
    Findley, Harry W.
    Zhou, Muxiang
    [J]. BLOOD, 2007, 110 (11) : 137B - 137B
  • [14] MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2
    Gu, L.
    Zhu, N.
    Findley, H. W.
    Zhou, M.
    [J]. LEUKEMIA, 2008, 22 (04) : 730 - 739
  • [15] MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2
    L Gu
    N Zhu
    H W Findley
    M Zhou
    [J]. Leukemia, 2008, 22 : 730 - 739
  • [16] Functional Analysis of the p53 Pathway in Neuroblastoma Cells Using the Small-Molecule MDM2 Antagonist Nutlin-3
    Van Maerken, Tom
    Rihani, Ali
    Dreidax, Daniel
    De Clercq, Sarah
    Yigit, Nurten
    Marine, Jean-Christophe
    Westermann, Frank
    De Paepe, Anne
    Vandesompele, Jo
    Speleman, Frank
    [J]. MOLECULAR CANCER THERAPEUTICS, 2011, 10 (06) : 983 - 993
  • [17] Downregulation of cyclin D1 sensitizes cancer cells to MDM2 antagonist Nutlin-3
    Ou, Wenbin
    Chen, Weicai
    Zhu, Jiaqing
    Eilers, Grant
    Li, Xuhui
    Yang, Peipei
    Li, Hailong
    Meng, Fanguo
    Fletcher, Jonathan
    [J]. CANCER RESEARCH, 2015, 75
  • [18] Downregulation of cyclin D1 sensitizes cancer cells to MDM2 antagonist Nutlin-3
    Yang, Peipei
    Chen, Weicai
    Li, Xuhui
    Eilers, Grant
    He, Quan
    Liu, Lili
    Wu, Yeqing
    Wu, Yuehong
    Yu, Wei
    Fletcher, Jonathan A.
    Ou, Wen-Bin
    [J]. ONCOTARGET, 2016, 7 (22) : 32652 - 32663
  • [19] Activation of the p53 pathway by the MDM2 antagonist nutlin-3 downregulates the DNA repair protein hABH2 and sensitizes glioma cells to chemotherapy
    Johannessen, Tor-Christian A.
    Prestegarden, Lars
    Grudic, Amra
    Tysnes, Bent B.
    Bjerkvig, Rolf
    [J]. CANCER RESEARCH, 2011, 71
  • [20] p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3
    Chappell, William H.
    Lehmann, Brian D.
    Terrian, David M.
    Abrams, Stephen L.
    Steelman, Linda S.
    McCubrey, James A.
    [J]. CELL CYCLE, 2012, 11 (24) : 4579 - 4588